Molecular imaging is a broad and dynamic field that encompasses a range of image technologies that allow physicians and researchers to noninvasively visualize biological processes at the cellular and molecular level. Currently, the vast majority of clinical applications of molecular imaging use radiolabeled compounds (radiopharmaceuticals) that are detected with gamma cameras, single-photon emission computed tomography (SPECT) or positron emission tomography (PET), depending on the type of radioactivity used. Molecular imaging techniques typically complement more anatomic-based imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI), and hybrid imaging modalities including SPECT/CT, PET/CT and more recently PET/MRI are available for clinical use. Together, multimodality molecular imaging can more accurately localize and characterize disease processes than either modality alone.

State-of-the-art imaging displays are a must for the healthcare arena, and today have an increasing capacity to offer large, high-resolution displays, color accuracy, calibrated brightness, advanced connectivity, optimized workflow and high contrast, just to name a few. A variety of vendors continue to improve the technology to better display imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), X-ray, positron emission tomography (PET), mammography and ultrasound, and to ensure screens remain DICOM (digital imaging and communications in medicine) compliant.

The U.S. Food and Drug Administration (FDA) announced its latest efforts in supporting the Bonn Call for Action on radiation protection.

The future of picture archiving and communication systems (PACS) is changing. What emerged more than 20 years ago with a bang and helped change the face of diagnostic imaging and productivity is now seeing its own changes as new technology advances. Functions that once were exclusive to PACS are shifting to different applications.

Governor Bobby Jindal signed the 24th density reporting bill (House Bill 186) into law. The Act, known as the Monica Landry Helo Early Detection Act, will become effective January 1, 2016.

Utah-based healthcare technology company Novarad is planning to provide workflow optimized virtualization from Sphere 3D Corp. to 400 healthcare facilities that currently use Novarad’s healthcare software.

University of Southampton scientists have discovered a link between coronary heart disease and osteoporosis, suggesting both conditions could have similar causes.

The spinal cord engages in its own learning of motor tasks independent of the brain, according to an imaging study published June 30th in the Open Access journal PLOS Biology. The results of the study — conducted by Shahabeddin Vahdat, Ph.D., Ovidiu Lungu, and principal investigator Julien Doyon, Ph.D., of the University of Montreal, Quebec, Canada — may offer new opportunities for rehabilitation after spinal cord injury.

Mevion Medical Systems announced delivery of the superconducting synchrocyclotron accelerator for its Mevion S250 proton therapy system for installation at University Hospitals (UH) Seidman Cancer Center and UH Rainbow Babies & Children's Hospital in Cleveland.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now